Intech Investment Management LLC Acquires New Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Intech Investment Management LLC purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 12,593 shares of the specialty pharmaceutical company's stock, valued at approximately $751,000. Intech Investment Management LLC owned approximately 0.06% of ANI Pharmaceuticals as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in ANI Pharmaceuticals by 1.4% in the first quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company's stock worth $90,314,000 after purchasing an additional 17,460 shares during the period. O Shaughnessy Asset Management LLC bought a new stake in ANI Pharmaceuticals in the 1st quarter valued at about $218,000. CANADA LIFE ASSURANCE Co raised its stake in ANI Pharmaceuticals by 7.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 13,036 shares of the specialty pharmaceutical company's stock worth $900,000 after buying an additional 909 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in shares of ANI Pharmaceuticals during the first quarter valued at approximately $289,000. Finally, California State Teachers Retirement System raised its position in shares of ANI Pharmaceuticals by 1.5% during the first quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company's stock worth $1,118,000 after purchasing an additional 233 shares during the period. Institutional investors and hedge funds own 76.05% of the company's stock.

Wall Street Analysts Forecast Growth

ANIP has been the topic of several research reports. HC Wainwright restated a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Piper Sandler began coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an "overweight" rating and a $68.00 price objective for the company. Truist Financial raised their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a report on Tuesday, October 22nd. StockNews.com lowered ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, September 7th. Finally, Raymond James increased their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a report on Wednesday, September 18th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $77.33.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP traded down $2.16 during trading hours on Friday, reaching $57.23. 224,908 shares of the company were exchanged, compared to its average volume of 218,858. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock has a market capitalization of $1.20 billion, a P/E ratio of -104.05 and a beta of 0.71. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81. The business's 50 day simple moving average is $58.22 and its 200-day simple moving average is $60.67.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping analysts' consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million for the quarter, compared to analysts' expectations of $144.37 million. During the same quarter in the previous year, the firm posted $1.05 EPS. ANI Pharmaceuticals's revenue was up 12.5% on a year-over-year basis. On average, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the business's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the sale, the chief executive officer now owns 370,378 shares of the company's stock, valued at $21,478,220.22. The trade was a 8.29 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last 90 days, insiders sold 33,981 shares of company stock worth $1,970,066. 12.70% of the stock is owned by company insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.